Completed PHASE2 INTERVENTIONAL 1-arm NCT00113360

RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma

Phase II Study of RAD001 Plus Octreotide Depot in Patients With Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma (Carcinoid, Islet Cell)

Sponsor: M.D. Anderson Cancer Center

Conditions Islet Cell Carcinoma Neuroendocrine Carcinoma

Interventions Octreotide Depot RAD001

Updated 8 times since 2017 Last updated: Apr 24, 2025 Started: Jan 31, 2005 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00113360, this PHASE2 trial focuses on Islet Cell Carcinoma and Neuroendocrine Carcinoma and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 8 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Jun 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Nov 2023 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Nov 2023 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States